Ironwood Pharmaceuticals Raises FY23 Revenue Outlook To $435M-$450M (From $420M-$435M) Vs. $427.88M Estimate
Portfolio Pulse from Benzinga Newsdesk
Ironwood Pharmaceuticals has increased its FY23 revenue outlook from $420M-$435M to $435M-$450M, surpassing the $427.88M estimate. The company also expects U.S. LINZESS net sales growth to be between 6% to 8%, up from the previous 3% to 5%. However, the adjusted EBITDA is expected to be around -$900 million, including a one-time charge of approximately $1.1 billion from the acquisition of VectivBio.
August 08, 2023 | 11:22 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Ironwood Pharmaceuticals' raised FY23 revenue outlook and increased LINZESS net sales growth expectations could positively impact its stock. However, the large one-time charge from the VectivBio acquisition may offset some of this positivity.
The raised revenue outlook and increased sales growth expectations are positive indicators for Ironwood Pharmaceuticals' performance, which could lead to a rise in its stock price. However, the significant one-time charge from the VectivBio acquisition could be a concern for investors, potentially offsetting some of the positive impact.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100